61例抗糖尿病药物不良反应报告分析

目的:分析我院抗糖尿病药物不良反应(ADR)发生的特点,为临床合理安全使用该药提供参考。方法:采用回顾性方法,对我院2009年9月～2011年9月临床上报的ADR报告进行统计分析。结果:抗糖尿病药物导致ADR病例61例,其中男30例(49.18%),女31例(50.82%);涉及药物共6类10种。ADR临床表现主要为神经系统(35.11%)、消化系统(21.28%)及心血管系统(14.89%)反应。结论:抗糖尿病药物可引发多系统的不良反应,应引起医护人员和患者的关注,注意监测。     

A propofol microemulsion with low free propofol in the aqueous phase: Formulation, physicochemical characterization, stability and pharmacokinetics

The purpose of this study was to develop a propofol microemulsion with a low concentration of free propofol in the aqueous phase. Propofol microemulsions were prepared based on single-factor experiments and orthogonal design. The optimal microemulsion was evaluated for pH, osmolarity, particle size, zeta potential, morphology, free propofol in the aqueous phase, stability, and pharmacokinetics in beagle dogs, and comparisons made with the commercial emulsion, Diprivan(?). The pH and osmolarity of the microemulsion were similar to those of Diprivan(?). The average particle size was 22.6±0.2nm, and TEM imaging indicated that the microemulsion particles were spherical in appearance. The concentration of free propofol in the microemulsion was 21.3% lower than that of Diprivan(?). Storage stability tests suggested that the microemulsion was stable long-term under room temperature conditions. The pharmacokinetic profile for the microemulsion showed rapid distribution and elimination compared to Diprivan(?). We conclude that the prepared microemulsion may be clinically useful as a potential carrier for propofol delivery.     

非典型抗精神病新药研究进展

精神分裂症发病机制复杂,治疗药物多以缓解症状为主要目的 ,临床尚无能有效治愈精神分裂症的药物。本文回顾了2007年以来美国食品药品管理局批准上市的治疗成人精神分裂症的非典型抗精神病药物,以期对精神分裂症的治疗提供参考。     

张秋娟教授从痰瘀论治垂体生长激素腺瘤经验

垂体瘤属颅内常见肿瘤,可归于祖国医学"脑瘤"范畴,西医治疗手段及疗效均很有限。张秋娟教授从事垂体瘤医、教、研多年,学验颇丰,执简驭繁地将垂体瘤纷繁复杂的中医病因病机概括为"痰瘀互结",并采用"化痰祛瘀"为治疗大法,临床收效显著。     

搜风通络方对老年单纯收缩期高血压患者TNF-α及hs-CRP的影响

目的：通过肿瘤细胞因子-α（TNF-α）、高敏C反应蛋白（hs-CRP）来探讨搜风通络方治疗老年单纯收缩期高血压（ISH）的作用机理。方法：60例老年单纯收缩期高血压患者采用随机双盲对照法分为治疗组和对照组各30例,对照组服用苯磺酸氨氯地平片治疗,治疗组在此基础上加用搜风通络方治疗,疗程16周,分别于治疗前后监测24h动态血压（ABPM）,检测TNF-α、hs-CRP。结果 ：搜风通络方能显著降低老年单纯收缩期高血压患者血压,改善动态动脉硬化指数（AASI）,降低TNF-α、hs-CRP水平（P〈0.05）。结论：搜风通络方通过降低TNF-α、hs-CRP水平来改善动脉硬化程度,降低血压。     

产后身痛中医药治疗研究进展

产后身痛是妇女在产褥期内,出现肢体或关节酸楚、疼痛等症状,病程缠绵,日久难愈,严重影响女性身心健康及生活质量。文章从辨证论治、阶段治疗、中成药治疗、外治法以及综合疗法方面对中医药治疗产后身痛的研究进展进行总结分析。中医药治疗产后身痛的疗效显著,但目前对产后身痛的研究中还存在一些不足之处有待完善。     

解毒药、通络药及生津药配伍对干燥综合征大鼠AQP5表达的对比分析

目的探讨解毒药、通络药及生津药配伍对干燥综合征大鼠AQP5的影响。方法将70只雌性SD大鼠随机分为7组,即解毒通络生津组（A）、解毒组（B）、通络组（C）、生津组（D）、强的松组（E）、生理盐水组（F）及正常对照组（G）。除正常对照组外,每只大鼠均经过造模,建立SS模型,正常对照组注射相同剂量生理盐水。各组分别给予解毒通络生津中药、清热解毒中药、活血通络中药、养阴生津中药、强的松、生理盐水治疗28d,正常对照组不做处理。观察大鼠饮水量的变化,采用逆转录聚合酶链式反应（RT—PCR）对颌下腺的AQP5进行半定量分析。结果解毒通络生津组大鼠饮水量明显减少,与其他各中药组及强的松组比较差异有统计学意义（P〈0．05）,通过RT—PCR半定量分析显示,解毒通络生津组AQP5的表达优于其他各组（P〈0．05）;生津组及强的松组AQP5的表达优于解毒组和通络组（P〈0．05）。结论生津药、解毒药及通络药配伍可改善大鼠口干症状,其机制可能与上调大鼠颌下腺AQP5的表达有关。     

胆汁酸受体TGR5激动剂研究进展

临床上依然需要新型的2型糖尿病治疗药物。胆汁酸受体TGR5是新发现的糖尿病药物靶点,一般认为TGR5激动剂可在降血糖的同时改善肥胖。本文介绍了受体TGR5的概况、与TGR5相关的生理功能,以及作为候选药物的甾体类和非甾体类TGR5激动剂的研究状况。     

LC-MS测定埃博霉素B血浆蛋白结合率

目的 建立液相色谱串联质谱(LC-MS)测定方法并检测犬以及人体埃博霉素B的血浆蛋白结合率.方法 建立LC-MS联合检测方法,以犬和人体血浆为对象,结合甲衡透析法检测埃博霉素B的血浆蛋白结合率.结果 3种浓度(100、50和10 ng/mL)埃博霉素B与犬血浆蛋白结合率分别为(85.4％±2.5％)、(81.3％±2.2％)和(83.7％±3 4％),与人体血浆蛋白结合率分别为(74.4％±3 8％)、(81.0％±2.9％)和(75.6％±2.2％),且灵敏度高,重现性好,操作简单.结论 埃博霉素B血浆蛋白结合率高,LC-MS可用于埃博霉素B血浆蛋白结合率的检测.     

Effectiveness and safety of massage for athletic injuries: A protocol for systematic review and meta-analysis

Background:Athletic injuries have been a major area of interest in the field of sports and clinical medicine. Implemented on people''s skin, muscles, and joints as an important part of complementary and alternative medicine (CAM), massage therapy has a positive effect on athletic injuries. This protocol is to provide the methods used to evaluate the effectiveness and safety of massage therapy for patients with athletic injuries.Methods:A systematic search will be performed in the following electronic databases for randomized controlled trials (RCTs) to evaluate the effectiveness and safety of massage therapy in treating athletic injuries: PubMed, the Cochrane Library, EMBASE and four Chinese databases (CNKI, Wan Fang, CBMdisc and VIP). Each database will be searched from inception to July 2021. The entire process will include study selection, data extraction, risk of bias assessment and meta-analysis.Results:A high-quality synthesis of current evidence of massage therapy for patients with athletic injuries will be provided.Conclusions:This systematic review will provide evidence for assessing the credibility of massage therapy for patients with athletic injuries.Dissemination and ethics:The results of this review will be disseminated through peer-reviewed publication. This review does not require ethical approval because all the data used in this systematic review and meta-analysis have already been published. Furthermore, all of these data will be analyzed anonymously during the review process.INPLASY registration number:INPLASY202170066.